Canada markets closed

RenovoRx, Inc. (RNXT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4900-0.0700 (-2.73%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.5600
Bid2.1400 x 3000
Ask2.7000 x 900
Day's Range2.3197 - 2.5600
52 Week Range1.5000 - 16.7400
Avg. Volume14,996
Market Cap22.576M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1850
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • Business Wire

    RenovoRx Reports Second Quarter 2022 Financial Results

    LOS ALTOS, Calif., August 15, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.

  • Simply Wall St.

    Will RenovoRx (NASDAQ:RNXT) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Business Wire

    RenovoRx Appoints James Ahlers as Chief Financial Officer

    LOS ALTOS, Calif., July 19, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.